Navigation auf


Science Alumni UZH

Public lecture: ensovibep – a journey from basic research to the development of a promising Covid-19 drug

The innovative team at Molecular Partners AG has succeeded in developing an effective drug for people suffering from Covid-19. This pharmaceutical company is a spin-off of the Department of Biochemistry of the Faculty of Mathematics and Natural Sciences of the University of Zurich: the technology was originally developed in the laboratory of Prof. Andreas Plückthun.


Tuesday, 08.02.2022, 12 p.m. to 1 p.m.

In their public lecture, Prof. Andreas Plückthun, Professor for Biochemistry at the University of Zurich and co-founder of Molecular Partners, together with Dr. Michael Tobias Stumpp, Chief Operating Officer, member of the Management Board and co-founder of Molecular Partners AG, will provide insights into the history of the development of an innovative technology and of the promising drug, now licensed to Novartis AG.

General Information

Date: Tuesday, 08.02.2022

Time: 12 p.m. to 1 p.m.

Due to the current situation, the lecture will be held virtually.


Media release Molecular Partners (10.01.2022)

Selection of reports in Media (German only)

10.01.2022 NZZ, Ein Schweizer Medikament gegen Sars-CoV-2 rückt näher: Novartis übernimmt die weiteren Vorbereitungen

10.01.2022, Finanz und Wirtschaft, Novartis kauft Moleculars Coronamedikament

10.01.2022 Tages Anzeiger, Kampf gegen Covid-19, Novartis fährt Produktion für ein neues Corona-Medikament hoch

12.01.2022 UZH News, Erfolgreiche Innovation, «Wir haben einen stabilen Wirkstoff geschaffen»

Weiterführende Informationen